SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as traders balance technical momentum against geopolitical uncertainty surrounding regional conflicts and pending diplomatic negotiations. Community sentiment remains sharply divided, with bulls pointing to robust institutional inflows and long-term scarcity as catalysts for a squeeze, while bears highlight risks from potential regulatory shifts and macroeconomic pressures.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending as investors closely monitor its correlation with Bitcoin's momentum and developments surrounding the Clarity Act, which remains a key catalyst for potential regulatory progress. The community is actively debating the stock's volatility and its role as a proxy for the broader crypto market, with many traders focused on critical support levels and the potential for a significant re-rate.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently at the center of a massive, retail-driven short squeeze, with the stock price skyrocketing as traders speculate that a supply-demand imbalance has trapped short sellers. The community is deeply divided between bulls celebrating an epic squeeze and bears warning of an inevitable, violent collapse fueled by high volatility and extreme option premiums.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is attracting attention as investors anticipate upcoming data presentations at the American Urological Association conference and potential progress toward a BLA submission. The community is actively debating the company's valuation gap compared to sector peers and monitoring technical breakout levels, while some long-term shareholders remain focused on the clinical potential of CAN-2409 to address unmet needs in prostate cancer.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate as investors weigh the company's aggressive and ongoing Bitcoin accumulation strategy against concerns regarding debt-funded dilution. Market participants are closely watching the stock's role as a levered proxy for Bitcoin, with sentiment split between those anticipating a major breakout tied to BTC price appreciation and others warning of unsustainable leverage and potential downside risks.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is surging following the release of positive registrational trial data for its CAR T-cell therapy, miv-cel, in treating Stiff Person Syndrome, with the company announcing plans for a BLA submission in early 2026. The community is buzzing over the therapy's potential as a 'first-in-class' treatment for autoimmune diseases, fueling speculation regarding a potential buyout or partnership given the firm's robust clinical results and large-scale manufacturing advancements.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG) is gaining traction as community members highlight its passive Solana reward mechanism, which distributes earnings every six hours without requiring traditional staking. Supporters are framing the asset as a resilient, "battle-tested" play, focusing on long-term project building and a deflationary model that remains a key point of discussion for those looking to capitalize on automated on-chain rewards.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is trending as investors monitor its aggressive Bitcoin treasury strategy and corporate moves, including a new ETF filing for digital credit assets. The community remains deeply polarized, with some bulls emphasizing institutional inflows and long-term Bitcoin upside, while vocal critics highlight past share dilution, reverse splits, and historical losses from Bitcoin purchases.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant market attention as investors digest a recent $23 billion acquisition of Exact Sciences, a move that consolidates the company's diagnostics footprint despite persistent concerns regarding near-term earnings pressure and guidance adjustments. Community sentiment remains split between long-term bulls highlighting the company's defensive 'Dividend King' status and potential for oncology growth, and vocal bears focused on recent 52-week lows, valuation concerns, and litigation risks surrounding their nutrition segment.

Dogelon Mars

Dogelon Mars continues to trend as investors speculate on potential synergies with Elon Musk's ventures and track the coin's historical meme status. Community sentiment remains polarized, with many holders focused on long-term accumulation and anticipation of future exchange listings, while others express frustration over stagnant price action and the lack of utility.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immix Biopharma (NASDAQ:IMMX) Trading Down 4.6%  - Time to Sell?

Immix Biopharma (NASDAQ:IMMX) Shares Down 4.6% - Time to Sell...

Immix Biopharma (NASDAQ:IMMX) Trading 12% Higher - Should You Buy?

Immix Biopharma (NASDAQ:IMMX) Stock Price Up 12% - Still a Buy...

Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat reports. One...

Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says

Mizuho raised their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Monday...

Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus...

Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX)

Citizens Jmp restated a "market outperform" rating and set a $23.00 price target on shares of Immix Biopharma in a research report on Friday...

Immix Biopharma (NASDAQ:IMMX) Given New $15.00 Price Target at HC Wainwright

HC Wainwright lifted their price objective on shares of Immix Biopharma from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday...

Immix Biopharma (NASDAQ:IMMX) Now Covered by Analysts at Morgan Stanley

Morgan Stanley began coverage on shares of Immix Biopharma in a research note on Wednesday. They set an "overweight" rating and a $20.00 price objective for the company...

Immix Biopharma (NASDAQ:IMMX) Shares Down 8.9% - Should You Sell?

Immix Biopharma (NASDAQ:IMMX) Trading Down 8.9% - What's Next...

Immix Biopharma (NASDAQ:IMMX) Trading Up 6.3% - What's Next?

Immix Biopharma (NASDAQ:IMMX) Trading Up 6.3% - Should You Buy...

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

IMMX
Immix Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IMMX News

IMMXImmix Biopharma Inc